Condition (MeSH)
Jaundice, Obstructive
ClinicalTrials.gov lists 56 trials for Jaundice, Obstructive or a narrower condition beneath it. POLYSAN Scientific & Technological Pharmaceutical Company has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
56 of the 56 trials are tagged with Jaundice, Obstructive itself; the rest are tagged with a narrower condition beneath it.
When did Jaundice, Obstructive trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 5 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 4 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 27 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Jaundice, Obstructive trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 6 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 24 |
| Observational | 19 |
How many Jaundice, Obstructive trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 25 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Jaundice, Obstructive trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| POLYSAN Scientific & Technological Pharmaceutical Company | 3 |
| Azienda USL Reggio Emilia - IRCCS | 1 |
Which drugs are being tested for Jaundice, Obstructive? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ursodeoxycholic Acid | 1 |
| Methylene Blue | 1 |
| Photofrin | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Remaxol | 3 |
| Acetate Ringer's Solution | 2 |
| neostigmine methylsulfate，raceanisodamine hydrochloride | 1 |
| Corticosteroids | 1 |
| trail cohort | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Jaundice, Obstructive? (73)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas. | BMC cancer | 2021 | Yes |
| Which patients benefit from preoperative biliary drainage in resectable pancreatic cancer? | Expert review of gastroenterology & hepatology | 2021 | Yes |
| Stent placement by EUS or ERCP for primary biliary decompression in pancreatic cancer: a randomized trial (with videos). | Gastrointestinal endoscopy | 2018 | Yes |
| Pathophysiological consequences of obstructive jaundice and perioperative management. | Hepatobiliary & pancreatic diseases international : HBPD INT | 2018 | Yes |
| Success and complications of percutaneous transhepatic biliary drainage are influenced by liver entry segment and level of catheter placement. | Abdominal radiology (New York) | 2018 | Yes |
Showing 5 of 73 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.